2-(3-Thienyl)-5,6-dihydroxypyrimidine-4-carboxylic acids as inhibitors of HCV NS5B RdRp

A series of 2-(3-thienyl)-5,6-dihydroxypyrimidine-4-carboxylic acid inhibitors of the hepatitis C virus (HCV) NS5B polymerase enzyme are reported. Sulfonyl urea substituted analogs in this series proved to be the most potent active site non-nucleoside inhibitors of NS5B reported to date. These compounds had low nanomolar enzyme inhibition across HCV genotypes 1–3 and showed single digit micromolar inhibition in the HCV replicon assay. This improved cell-based activity allowed the binding mode of these compounds to be probed by selection of resistant mutations against compound 21. The results generated are in broad agreement with the previously proposed binding model for this compound class.

A series of 2-(3-thienyl)-5,6-dihydroxypyrimidine-4-carboxylic inhibitors of the hepatitis C virus (HCV) NS5B polymerase enzyme are reported. Extensive SAR around the thiophene moiety led to the identification of the sulfonyl urea substituent as optimal in the HCV replicon assay. Mutations that confer resistance to these compounds are described.Figure optionsDownload as PowerPoint slide